Plain-English translation of NCT06647680 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether treating advanced rectal cancer with a combination of two chemotherapy drugs (Oxaliplatin and Capecitabine) plus an immune-boosting drug called Tislelizumab before surgery can help patients have better results. The immune-boosting medication works by helping your body's own immune system fight the cancer cells. Researchers want to see if this three-drug combination given for 9 weeks before surgery will shrink tumors and make surgery more effective.
Standard treatment for advanced rectal cancer typically uses chemotherapy, but researchers believe adding an immune-boosting medication might help the body fight cancer more effectively and improve long-term survival. This trial is testing whether this new combination approach works better than traditional treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive the three-drug combination (two chemotherapy drugs plus the immune-boosting medication) for 9 weeks in three cycles. During this time, you'll have regular visits for blood tests and imaging scans. After completing the medication, you'll rest for 2 weeks and then have surgery. Following surgery, doctors will decide on any additional treatment based on what they find. You'll then be followed with check-ins every 3 months for 3 years to monitor your health and survival.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China